江苏凯伦建材股份有限公司投资者关系活动记录表 问题三、请介绍下公司本次收购标的公司业绩承诺等情况 公司本次收购事项，标的公司股东苏州矽彩光电科技有限公司、实际控制人陈显锋 承诺：标的公司 2025 年度、2026 年度、2027 年度实现净利润分别不低于 5,500.00 万元、 7,500.00 万元、11,000.00 万元，即累积实现的净利润为 24,000 万元。 问题四、请介绍下公司本次收购标的公司后的公司治理情况 等交割完成后，标的公司将设董事会，董事会由 3 人组成，2 名由公司委派，1 名 由其他股东委派；在标的公司应当设置职工董事的情况下，董事会由 5 人组成，3 名由 公司委派；董事长为目标公司法定代表人，由其他股东委派的董事担任；标的公司不设 监事会、不设监事。 标的公司实行董事会领导下的总经理负责制，在业绩承诺期间，在标的公司董事会 的授权下总经理拥有日常经营决策管理权，并保证管理团队在业绩承诺期内稳定。 标的公司总经理由董事长提名，董事会聘任。公司委派的董事按照目标公司章程行 使权利、履行义务。 标的公司设财务总监（财务负责人），由公司推荐人选，董事会聘任，标的公司管 理层应充分保证 ...

Group 1: Financial Performance - In 2024, the company achieved a revenue of 770 million RMB, a year-on-year increase of 2.9% [2] - Q1 2025 revenue reached 197 million RMB, growing by 2.6% year-on-year [2] - The gross profit margin for 2024 was 58.6%, up by 1 percentage point year-on-year; Q1 2025 gross profit margin was 58.4%, an increase of 0.4 percentage points [2] - The net profit attributable to shareholders for 2024 was 176.79 million RMB, a 12.2% increase year-on-year; Q1 2025 net profit was 47.15 million RMB, growing by 11.7% [2] - The net profit margin for 2024 was 23.0%, up by 1.9 percentage points year-on-year; Q1 2025 net profit margin was 23.9%, also an increase of 1.9 percentage points [2] Group 2: Expense Analysis - In 2024, total sales expenses were 141.01 million RMB, down by 4.4% year-on-year; Q1 2025 sales expenses were 33.94 million RMB, decreasing by 5.4% [3] - Management expenses for 2024 totaled 85.75 million RMB, an increase of 8.8% year-on-year; Q1 2025 management expenses were 18.79 million RMB, down by 20.5% [3] - R&D expenses in 2024 amounted to 34.99 million RMB, up by 25.0% year-on-year; Q1 2025 R&D expenses were 9.53 million RMB, increasing by 37.5% [3] Group 3: Market Trends and Product Performance - The lens industry is experiencing a shift towards high-end products, with a notable growth in demand for advanced products due to consumer upgrades and domestic replacements [3] - The company's lens business grew by 8.72% year-on-year, excluding the negative impacts from overseas and raw material businesses [3] - The PMC Ultra Bright series saw a revenue increase of nearly 45.6% in 2024, with three star products accounting for 54.6% of regular lens revenue [3] - The "Easy Control" series for myopia management achieved sales of 41.58 million RMB in Q4 2024, a year-on-year growth of 23.6% [3] Group 4: Strategic Initiatives - The company has permanently exited price wars since 2019, which has garnered goodwill from channels and customers [6][7] - A new product, the Easy Control Pro2.0, was launched, which is believed to have superior control effects compared to previous models [8] - The company is focusing on customer development, particularly in the medical field, and has initiated a seed customer program to support key clients [8] - A new marketing strategy was announced with the endorsement of a new spokesperson, emphasizing the importance of the "Easy Control" product line [9] Group 5: Future Outlook - The penetration rate for defocus lenses is currently around 7% to 8%, with a significant growth potential as over 120 million children in China require them [5] - The company anticipates sustained growth in the defocus lens market despite recent price competition, as external pressures have begun to ease [6] - The company is also exploring the smart glasses market, focusing on providing complete solutions and addressing challenges in fitting and service [10][11]

证券代码：002536 证券简称：飞龙股份 飞龙汽车部件股份有限公司投资者关系活动记录表 编号：2025-014 投资者关系活动 类别 ☑特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 ☑现场参观 □其他（电话会议） 参与单位名称及 人员姓名 林锐投资 姬永锋 华龙投资 邓鹏怡 中原证券 龙羽洁 瑞达基金 俞力杨 依脉数据科技 贲国肖等机构及个人投资者 10 余位 时间 2025 年 4 月 23 日 地点 公司子公司上海飞龙新能源汽车部件有限公司（以下简称"上 海飞龙"） 上市公司接待人 员姓名 副总经理、董事会秘书：谢国楼 子公司上海飞龙总经理：宋宏利 投资者关系活动 主要内容介绍 一、副总经理、董事会秘书谢国楼介绍公司情况 飞龙汽车部件股份有限公司（以下简称"公司"）始建于 1952 年，至今已有 70 多年的发展历史，是一家致力于热管理系 统方案解决的上市公司。 公司发展主要分为两个阶段，第一个阶段是 2017 年之前， 公司着力汽车热管理部件产品的研发、生产和销售，比如机械 水泵、排气歧管、涡轮增压器壳体（以下简称"涡壳"）、电 子泵系列产品、温控阀系列产品和热管理温 ...

Group 1: Financial Performance - In 2024, the company achieved total revenue of 11.09 billion CNY, a year-on-year increase of 6.27% [2] - The net profit attributable to shareholders was 2.55 billion CNY, impacted by an asset impairment provision of 38.37 million CNY [2] - In Q1 2025, the company reported total revenue of 2.72 billion CNY, a year-on-year growth of 16.63%, with a net profit of 90.47 million CNY, up 40.92% [2][3] Group 2: R&D and Innovation - The R&D team expanded to 523 members with an investment of 216 million CNY, representing 19.49% of total revenue, and achieved a 6.35% increase in R&D spending [4] - The company received approvals for several innovative products, including the PCR-11 gene product and multiple medical devices, leading to a total of 32 Class III medical device registrations [4][5] Group 3: Domestic Market Performance - Domestic sales in 2024 generated revenue of 777 million CNY, a decrease of 1.08%, but Q1 2025 showed signs of recovery [6] - The company has a specialized service team of nearly 400 people, providing high-quality products to over 500 hospitals [6][7] Group 4: International Market Growth - International sales and pharmaceutical business achieved revenue of 332 million CNY in 2024, a year-on-year increase of 28.61% [8] - The company established a global operational network with subsidiaries in Singapore, Hong Kong, and Canada, and a logistics center in the Netherlands [8] Group 5: Strategic Partnerships - The company has expanded its partnerships with pharmaceutical companies, providing comprehensive diagnostic solutions across multiple platforms [9] - Collaborations with major pharmaceutical firms have led to the development of diagnostic products for various cancer treatments, enhancing the company's market position [9] Group 6: Industry Trends and Regulatory Environment - The oncology treatment field is entering a "precision medicine" era, with increasing demand for genetic testing driven by rising cancer incidence and advancements in targeted therapies [11] - Regulatory policies are tightening, emphasizing compliance in genetic testing and requiring approvals for diagnostic tools, which may benefit compliant leading enterprises [12] Group 7: Product Coverage and Market Penetration - The company's products are not yet included in the national medical insurance, but genetic testing projects have been incorporated into local insurance schemes in several provinces [13] - The company focuses on managing key raw material suppliers to mitigate risks associated with international trade [14]

Group 1: Impact of Tariff Policies - Changes in tariff policies present both opportunities and challenges for the scientific instrument industry, leading to increased procurement costs for imported instruments and related consumables [2] - The high dependence on imports in the scientific instrument sector creates uncertainty and insecurity among domestic users, which can be strategically advantageous for local manufacturers [2] - The company plans to increase R&D investment in 2025 to capitalize on these strategic opportunities and enhance product offerings tailored to domestic customer needs [2] Group 2: Business Structure Adjustments - Recent adjustments in the company's business structure have resulted in improved gross margins and a recovery in net profit margins [3] - The company aims to further invest in its advantageous business segments to promote growth while maintaining a stable recovery in net profit margins [3] Group 3: Carbon Monitoring Equipment - The subsidiary Lingxi Optoelectronics has developed high-precision greenhouse gas analysis instruments, with significant contract growth expected in 2024 due to favorable domestic carbon monitoring policies [3] - The company anticipates a positive outlook for its carbon monitoring segment as market policies are implemented [3] Group 4: Market Demand and Product Development - The laboratory instrument sector is projected to maintain good growth, particularly in mass spectrometry, which has strong technical advantages and customer recognition [3] - The environmental monitoring segment achieved approximately 10% growth last year, with stable market conditions and a focus on increasing market share [3] Group 5: Future of Intelligent Instruments - The company envisions a future where analytical instruments evolve into "analysis robots," integrating AI capabilities for enhanced decision-making and operational efficiency [4] - Current developments include a modern environmental management model that leverages AI and new intelligent monitoring equipment such as drones and robotic dogs [4] Group 6: Goodwill Impairment - The company's current goodwill is approximately 200 million, primarily related to specific subsidiaries, with future impairment assessments dependent on individual company performance [4]

Financial Performance - In 2024, the company achieved operating revenue of 10.792 billion yuan, a year-on-year increase of 12.27% [2] - The net profit attributable to shareholders reached 135 million yuan, up 53.99% year-on-year [2] - In Q1 2025, the company reported operating revenue of 3.427 billion yuan, a growth of 34.29% [2] - The net profit attributable to shareholders for Q1 2025 was 82.72 million yuan, reflecting a year-on-year increase of 61.69% [2] Asset and Liability Overview - As of the end of 2024, total assets amounted to 7.928 billion yuan, a growth of 0.90% from the beginning of the year [2] - Total liabilities were 4.122 billion yuan, increasing by 0.61% [2] - Net assets stood at 3.765 billion yuan, up 1.77% [2] - By the end of Q1 2025, total assets reached 8.673 billion yuan, a growth of 6.73% [2] - Total liabilities increased to 4.628 billion yuan, a rise of 12.47% [2] - Net assets were 3.736 billion yuan, reflecting a growth of 0.54% [2] Business Segments - The company generated 4.501 billion yuan from surfactants (including personal care products), a 32.43% increase year-on-year [3] - The gross profit margin for surfactants was 6.57%, up 1.52 percentage points from the previous year [3] - Sales volume of surfactants reached 809,000 tons, a growth of 40.15% [3] - Oil chemical products generated 6.121 billion yuan in revenue, a 3.1% increase year-on-year [3] - The gross profit margin for oil chemical products was 6.69%, up 0.21 percentage points [3] - Sales volume of oil chemical products was 805,900 tons, down 5.28% [3] Production Capacity - The company has an annual production capacity of 100,000 tons for liquid detergents in Jiangsu, and 500,000 tons each in Henan and Sichuan for personal care products [4] - Total OEM/ODM processing capacity for personal care products has reached 1.1 million tons [4] Strategic Advantages - The company leverages its technical and scale advantages in surfactant production to create an integrated supply chain model for personal care product processing [5] - The company engages in futures hedging to mitigate risks from raw material price fluctuations [5] - The company has established a strong R&D foundation, being recognized as a national high-tech enterprise [6] - The company aims to enhance its market share and competitiveness through continuous technological innovation and industry chain extension [6]

Financial Performance - In 2024, the company achieved total revenue of CNY 506,298.69 million, a year-on-year increase of 23.61% [4] - The net profit attributable to shareholders was CNY 60,789.54 million, up 27.42% compared to the previous year [5] - Sales of injection molding machines reached CNY 355,520.39 million, growing by 28.80% [4] - Sales of die-casting machines totaled CNY 89,349.01 million, with a growth of 14.53% [4] - Rubber machine sales were CNY 22,195.78 million, increasing by 21.42% [5] - In Q1 2025, total revenue was CNY 118,692.32 million, a 24.32% increase year-on-year, with net profit rising by 14.29% [5] Market Strategy - The company has over 40 overseas distributors, covering more than 90 countries and regions [9] - In 2024, foreign sales revenue was CNY 139,455.90 million, reflecting a growth of 27.45% [9] - The company is expanding its global footprint with factories in India and service centers in Germany, Brazil, and Vietnam [9] - The automotive industry is the largest sector for the company, with a positive outlook in the domestic new energy vehicle market [5] Research and Development - R&D expenditure in 2024 was CNY 24,586.21 million, a 15.78% increase, representing 4.86% of total revenue [8] - The company has over 900 R&D personnel and holds more than 400 patents, including 74 invention patents [8] Product Innovation - The company has developed a semi-solid magnesium alloy injection molding machine for high-performance, lightweight components in new energy vehicles [7] - Continuous investment in smart manufacturing has led to the successful operation of the fifth factory, with plans for advanced smart warehousing and manufacturing bases [10] - The all-electric injection molding machine segment is experiencing sustained growth, with a focus on performance, quality, and environmental standards [11] Future Outlook - The company aims to enhance operational management and stability, striving for more orders and better service to shareholders in 2025 [11] - The global headquarters' foundation ceremony marks the beginning of a new phase in the company's globalization efforts [11]

Financial Performance and Shareholder Returns - In 2024, the company plans to distribute cash dividends of 18.7 billion RMB, accounting for 35% of the net profit attributable to the parent company [3][36] - The company aims to repurchase and cancel shares worth between 15 billion to 20 billion RMB annually [3][36] - From 2015 to 2024, the company has implemented cash dividends for 10 consecutive years, totaling nearly 22 billion RMB [3][37] - The company has repurchased A shares for over 5.6 billion RMB and B shares for nearly 1 billion HKD from 2020 to 2024 [3][37] Depreciation and Cash Flow - In 2024, the company's depreciation is expected to be approximately 38 billion RMB, with an increase anticipated due to new projects being put into operation [2] - The net cash flow from investment activities remains high, projected to exceed 30 billion RMB in 2024 [5][6] Strategic Development and Market Position - The company is focusing on the "Screen and IoT" strategy, aiming to integrate more functionalities into displays and expand into various application scenarios [7][8] - The company has established a "1+4+N+Ecosystem" development framework, emphasizing semiconductor display as the core capability [8][9] - The company is actively pursuing high-potential areas such as IoT innovation, sensing, MLED, and smart medical engineering [9][10] Market Trends and Product Development - The global automotive display panel shipment is expected to reach 230 million units in 2024, with a year-on-year growth of 6.3% [31] - The company aims to produce 1.7 billion OLED units in 2025, up from 1.4 billion in 2024 [32] - The company has successfully launched Micro LED products, achieving high brightness and contrast ratios, and plans to continue expanding this technology [28][55] Risk Management and Market Adaptation - The company has a robust risk management mechanism to address potential market challenges, including a dedicated team for monitoring risks [26][34] - The direct export to the US is minimal, thus limiting the impact of US tariffs on the company's operations [19][24] Innovation and Future Outlook - The company is committed to advancing technologies such as Micro LED and exploring new applications in the healthcare sector [28][55] - The company is optimistic about the future of the semiconductor display industry, focusing on sustainable growth and technological advancements [47]

福建南平太阳电缆股份有限公司 | | 客户个性化需求；明确市场定位，精准触达目标客户，提高营销效 | | --- | --- | | | 率和效果，降低营销成本；持续进行成本分析，通过精益生产和持 | | | 续改进的方法，简化生产流程，减少浪费，节能降耗，从而提升公 | | | 司盈利能力。谢谢关注。 | | | 9、公司 2024 年电线电缆和铜加工的销售量和生产量均有所 | | | 下降，请问公司如何看待这一趋势？未来有哪些具体措施来提升市 | | | 场竞争力？ | | | 答：2024 年电线电缆和铜加工的销售量和生产量均有所下降， | | | 主要是市场需求不足所致。 | | | 公司为了适应市场环境的变化，进行营销改革，优化生产与报 | | | 价环节，采取"寸土必守、寸土必争"的积极销售策略，把更多的营 | | | 销职能授予分销商，使其快速响应市场。进一步区域深耕巩固省内 | | | 市场，持续发展县级分销网络，提升太阳产品在县级市场的占有率。 | | | 同时，积极发展省外代理网络；着力开拓各省电力公司的配网项目， | | | 提升电力市场的占有率；针对全国性的大型客户进行定向营销，提 | ...

Group 1: Financial Performance and Projections - The company's expected net profit for the year is 321 million yuan, with measures in place to ensure cash flow and profit stability [1] - Revenue decreased by 5.13% year-on-year, and net profit dropped by 45.48% due to weak downstream demand and increased competition [2][3] - Financial expenses increased significantly due to foreign exchange losses of 4.8744 million yuan, compared to a gain of 21.6833 million yuan in the previous year [2] Group 2: Operational Strategies - The company is expanding its production capacity for wet-process precipitated magnesium oxide from 50,000 tons to 60,000 tons to meet market demand [2] - Efforts are being made to control costs and improve management efficiency to enhance net profit margins [2] - The company is focusing on overseas market expansion and optimizing its production base to increase profit margins [1] Group 3: Cash Flow Management - The company has maintained good cash flow due to strict control over accounts receivable and improved operational efficiency [2] - Investment expenditures have increased significantly to enhance smart manufacturing and environmental standards [3] Group 4: Market Conditions and Pricing Strategy - The company is addressing rising upstream prices by communicating with downstream customers and enhancing cost control measures [3] - The impact of international political and economic conditions has led to increased financial costs and operational challenges [2][3]